|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500100104 |
|
最近更新日期: Date of Last Refreshed on: |
2025-04-02 16:38:34 |
|
注册时间: Date of Registration: |
2025-04-02 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
ERAS理念麻醉下颊针疗法和耳穴压豆对日间乳腺纤维瘤切除术患者术后疲劳综合征的影响 |
|
Public title: |
Effect of buccal needle therapy and auricular pressure beans under ERAS conceptual anaesthesia on postoperative fatigue syndrome in patients undergoing daytime breast fibroidectomy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
ERAS理念麻醉下颊针疗法和耳穴压豆对日间乳腺纤维瘤切除术患者术后疲劳综合征的影响 |
|
Scientific title: |
Effect of buccal needle therapy and auricular pressure beans under ERAS conceptual anaesthesia on postoperative fatigue syndrome in patients undergoing daytime breast fibroidectomy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄超群 |
研究负责人: |
黄超群 |
|
Applicant: |
Chaoqun Huang |
Study leader: |
Chaoqun Huang |
|
申请注册联系人电话: Applicant telephone: |
+86 138 5779 3807 |
研究负责人电话:
Study leader's |
+86 138 5779 3807 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
104409852@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
104409852@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国浙江省温州市鹿城区学院西路109号 |
研究负责人通讯地址: |
中国浙江省温州市鹿城区学院西路109号 |
|
Applicant address: |
109 Xueyuan Road West, Lucheng District, Wenzhou, Zhejiang, China |
Study leader's address: |
109 Xueyuan Road West, Lucheng District, Wenzhou, Zhejiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
325000 |
研究负责人邮政编码: Study leader's postcode: |
325000 |
|
申请人所在单位: |
温州医科大学附属第二医院育英儿童医院 |
||
|
Applicant's institution: |
Yuying Children's Hospital, the Second Affiliated Hospital of Wenzhou Medical University |
||
|
研究负责人所在单位: |
温州医科大学附属第二医院 |
||
|
Affiliation of the Leader: |
Yuying Children's Hospital, the Second Affiliated Hospital of Wenzhou Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审(2025-K-43-01) |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
温州医科大学附属第二医院 温州医科大学附属育英儿童医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of The Second Affiliated Hospital of Wenzhou Medical University, Yuying Children's Hospital affiliated to Wenzhou Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-02-19 00:00:00 | ||
|
伦理委员会联系人: |
陈苑 |
||
|
Contact Name of the ethic committee: |
Yuan Chen |
||
|
伦理委员会联系地址: |
浙江省温州市龙湾区温州大道东段1111号 |
||
|
Contact Address of the ethic committee: |
1111 East Section of Wenzhou Dadao,Longwan District,Wenzhou City,Zhenjiang Province,China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 137 5849 6849 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
feykikcy@126.com |
|
研究实施负责(组长)单位: |
温州医科大学附属第二医院育英儿童医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Yuying Children's Hospital, the Second Affiliated Hospital of Wenzhou Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
浙江省温州市鹿城区学院西路109号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
109 Xueyuan Road West, Lucheng District, Wenzhou, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
医院临床试验科研基金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Clinical trial grant of hospital |
||||||||||||||||||||||
|
研究疾病: |
乳腺纤维瘤 |
||||||||||||||||||||||
|
Target disease: |
breast fibroid |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)明确颊针疗法和耳穴压豆是否能减轻患者的术后疲劳感,以及减轻的具体程度和持续时间。 (2)探究颊针疗法和耳穴压豆对不同疲劳维度的影响差异。 (3)观察患者术后的身体机能指标,判断颊针疗法和耳穴压豆是否有助于加速患者身体各项机能的恢复。 (4)分析在 ERAS 理念麻醉下结合颊针疗法和耳穴压豆,是否能够实现缩短患者的住院时间,提高医疗资源的利用效率,同时也减轻患者的住院负担。 (5)验证颊针疗法和耳穴压豆这两种中医适宜技术在术后康复中的有效性和安全性,为其在临床中的广泛推广应用提供有力的证据支持,促进中医技术与现代西医手术治疗的更好结合,拓展中医在外科领域的应用范围。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To clarify whether buccal needle therapy and auricular pressure beans reduce patients' postoperative fatigue, as well as the specific degree and duration of reduction. (2) Explore the differences in the effects of buccal needle therapy and auricular pressure beans on different fatigue dimensions. (3) To observe the patients‘ postoperative body functions and determine whether buccal needle therapy and auricular acupoint pressure beans can help accelerate the recovery of the patients’ body functions. (4) To analyse whether the combination of buccal needle therapy and auricular acupressure under ERAS anaesthesia can shorten the patients' hospital stay, improve the efficiency of medical resources, and reduce the burden of hospitalization on the patients at the same time. (5) To verify the effectiveness and safety of the two TCM appropriate techniques, buccal needle therapy and auricular acupoint pressure beans, in postoperative rehabilitation, to provide strong evidence support for their widespread application in clinical practice, to promote better integration of TCM techniques with modern Western surgical treatments, and to expand the scope of application of TCM in the field of surgery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.自愿参加本实验并签署知情同意书 2.美国麻醉医师协会(ASA)体格情况分级I-II级 3.单侧乳腺纤维瘤肿瘤直径为1-3cm受试者 4.择期行乳腺微创旋切术的日间手术受试者 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Voluntarily participate in this experiment and sign the informed consent form. 2.American Society of Anaesthesiologists (ASA) Physical Condition Classification I-II 3.Unilateral breast fibroma tumour diameter 1-3cm subjects 4.Day surgery subjects undergoing elective minimally invasive rotational mastectomy |
||||||||||||||||||||||
|
排除标准: |
1.年龄<18周岁或>40周岁 2.肥胖(BMI>40) 3.耳面部畸形、皮肤疾病或外伤者 4.极度虚弱及低血糖患者 5.近期有使用针灸 6.有心脏功能异常,有严重肝、肾功能异常或糖尿病,凝血功能异常 7.有药物过敏史或金属过敏史 8.有酗酒或药物滥用史 9.有精神疾患不能配合、服用精神类药物及口头交流困难 10.对本研究所用药物有禁忌证的患者 11.长期熬夜、吸烟、饮酒等不良习惯 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Age < 18 years old or > 40 years old 2.Obesity (BMI>40) 3.Ear and facial deformities, skin diseases or traumatic injuries 4.Extremely weak and hypoglycaemic patients 5.Recent use of acupuncture 6.Abnormal heart function, serious liver or kidney function or diabetes mellitus, abnormal coagulation function 7.History of drug allergies or metal allergies 8.History of alcohol or drug abuse 9.Mental illness that prevents co-operation, psychotropic medication and verbal communication difficulties 10.Patients with contraindications to the drugs used in this study 11.Bad habits such as staying up late, smoking and drinking for a long time |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2026-07-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-04-02 00:00:00 至 To 2025-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究过程中固定一位与研究无关的麻醉工作者按照随机编码表分为三组,随访观察者由非研究人员的专业麻醉医师承担。在药物编盲的同时,由产生盲底的统计人员为每个随机编码准备一份应急信件。此信件密封有该编码的真实组别,应急信封由相关研究负责人保存。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
An anaesthesia worker unrelated to the study was fixed during the study and divided into three groups according to the random coding table, and the follow-up observer was assumed by a specialist anaesthesiologist who was not a member of the study staff. A contingency letter was prepared for each randomised code by the statistician who generated the blinded base while the drugs were blinded. This letter was sealed with the true group for that code and the contingency envelope was kept by the relevant study leader. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
研究过程中固定一位与研究无关的麻醉工作者按照随机编码表分为三组,随访观察者由非研究人员的专业麻醉医师承担。在药物编盲的同时,由产生盲底的统计人员为每个随机编码准备一份应急信件。此信件密封有该编码的真实组别,应急信封由相关研究负责人保存。 本研究生成的全部处理编码(包含随机数产生参数和种子数)以书面文件的形式密封,交由临床研究负责单位和主要研究者保存,该盲底应妥善保存至第二次揭盲。 |
|
Blinding: |
An anaesthesia worker unrelated to the study was fixed during the study and divided into three groups according to the random coding table, and the follow-up observer was assumed by a specialist anaesthesiologist who was not a member of the study staff. A contingency letter was prepared for each randomised code by the statistician who generated the blinded base while the drugs were blinded. This letter was sealed with the true group of the code and the contingency envelope was kept by the relevant study leader. The entire treatment code generated for this study (including the random number generation parameters and the number of seeds) is sealed in a written document and kept by the unit in charge of the clinical study and the principal investigator, and this blinded base should be properly stored until the second blinding. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2040年1月1日,国家生物信息中心 https://ngdc.cncb.ac.cn/gsub/ |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
2040-1-1; China National center for Bioinformation (https://ngdc.cncb.ac.cn/gsub/) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form, CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |